Stockscreener 앱 받기
19.94
2.87%
-0.59
전일 마감가:
$20.53
열려 있는:
$20.53
하루 거래량:
2.24M
Relative Volume:
0.82
시가총액:
$2.52B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-9.8227
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
-26.96%
1개월 성능:
-21.22%
6개월 성능:
+0.96%
1년 성능:
-32.93%
1일 변동 폭
$19.76
$20.70
1주일 범위
$19.76
$26.55
52주 변동 폭
$16.10
$31.17
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.94 | 2.60B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases - MSN
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - Yahoo Finance
Market Trends: Does Apellis Pharmaceuticals Inc stock have upside surprise potential2025 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
Apellis stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
Apellis Pharma VP Chopas sells $19k in shares By Investing.com - Investing.com Canada
Apellis Pharma chief business officer sells $39k in APLS stock - Investing.com Canada
Mark Jeffrey Delong Sells 1,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells $19,371.87 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 3,856 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 2,618 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares - MarketBeat
David Watson Sells 5,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharma CFO Sullivan sells $85,553 in shares By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $128k in shares By Investing.com - Investing.com Canada
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Press Telegram - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 5.8% on Analyst Downgrade - MarketBeat
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - sharewise.com
Assessing Apellis Pharmaceuticals (APLS) Valuation After 2025 Revenue Update And Pipeline Progress - Sahm
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Yahoo Finance
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
APLS: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
Cantor Fitzgerald Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $35.00 - MarketBeat
Forecasting The Future: 9 Analyst Projections For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $28.00 by Analysts at Needham & Company LLC - MarketBeat
Needham lowers Apellis Pharmaceuticals stock price target on Syfovre concerns - Investing.com UK
Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
APLS: Needham Maintains Buy Rating, Lowers Price Target to $28 | - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Analysis: A 50% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Strategic Updates - TradingView — Track All Markets
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's What Happened - MarketBeat
Apellis Pharmaceuticals (APLS) Is Up 9.8% After Strong SYFOVRE Demand Lifts Preliminary 2025 Revenues - Sahm
Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference - MarketBeat
Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference - TechStock²
Goldman Sachs reiterates Sell rating on Apellis stock amid revenue miss - Investing.com Canada
Apellis (APLS) Shares Plummet Over 17% - GuruFocus
Apellis Pharmaceuticals Reports Preliminary 2025 Revenues of $689 Million, Highlights Growth in SYFOVRE and EMPAVELI Sales - Quiver Quantitative
Apellis Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
SG Americas Securities LLC Purchases 372,289 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Why (APLS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE? - simplywall.st
Aug Breakouts: Is Apellis Pharmaceuticals Inc. stock near bottom after declineMarket Performance Recap & Daily Price Action Insights - ulpravda.ru
Can Apellis Pharmaceuticals Inc. stock sustain institutional interest2025 Investor Takeaways & AI Powered Buy/Sell Recommendations - ulpravda.ru
Can Apellis Pharmaceuticals Inc. (1JK) stock surprise with quarterly resultsJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Apellis Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - Улправда
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersBlue Chip Stock Analysis & Superior Wealth Strategies - bollywoodhelpline.com
How buybacks impact Apellis Pharmaceuticals Inc. stock value2025 Buyback Activity & Smart Swing Trading Techniques - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekers - ulpravda.ru
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아펠리스 주식 (APLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DeLong Mark Jeffrey | Chief Business & Strat Officer |
Jan 13 '26 |
Sale |
22.19 |
1,780 |
39,493 |
83,058 |
| Deschatelets Pascal | Chief Scientific Officer |
Jan 13 '26 |
Sale |
22.19 |
2,277 |
50,520 |
1,158,219 |
| Francois Cedric | Chief Executive Officer |
Jan 13 '26 |
Sale |
22.19 |
10,186 |
225,999 |
321,419 |
| Nicholson Nur | Chief Technical Officer |
Jan 13 '26 |
Sale |
22.19 |
2,618 |
58,086 |
81,046 |
| Sullivan Timothy Eugene | Chief Financial Officer |
Jan 13 '26 |
Sale |
22.19 |
3,856 |
85,554 |
107,080 |
| Watson David O. | General Counsel |
Jan 13 '26 |
Sale |
22.19 |
5,780 |
128,242 |
98,838 |
4.73%
0.92%
자본화:
|
볼륨(24시간):